[go: up one dir, main page]

AR068875A1 - Derivados de 4-5-dihidro-5-oxo-imidazol,composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos como inhibidores de receptores de npy y2 no peptidicos, para el tratamiento de trastornos de ansiedad , depresion, trastornos metabolicos y endocrinos. - Google Patents

Derivados de 4-5-dihidro-5-oxo-imidazol,composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos como inhibidores de receptores de npy y2 no peptidicos, para el tratamiento de trastornos de ansiedad , depresion, trastornos metabolicos y endocrinos.

Info

Publication number
AR068875A1
AR068875A1 ARP080104490A ARP080104490A AR068875A1 AR 068875 A1 AR068875 A1 AR 068875A1 AR P080104490 A ARP080104490 A AR P080104490A AR P080104490 A ARP080104490 A AR P080104490A AR 068875 A1 AR068875 A1 AR 068875A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
group
oxo
hydrogen
methodolostic
Prior art date
Application number
ARP080104490A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR068875A1 publication Critical patent/AR068875A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicacion 1: Un compuesto de la formula 1: en donde: R3 y R3a representan juntos oxo (=0), o R3 representa hidrogeno, y R3a representa hidroxilo, o R3 representa hidrogeno, y R3a representa hidrogeno, y X representa -C(O)-NR6-; -NR6-C(O)-, -NR6-C(O)-NR6-; n representa 0, 1 o 2; m representa 0, 1, 2 o 3; R1 representa hidrogeno, o un sustituyente diferente de hidrogeno, R2 representa un grupo arilo opcionalmente sustituido, un grupo cicloalquilo opcionalmente sustituido, un grupo hetero-arilo opcionalmente sustituido, un grupo heterociclilo opcionalmente sustituido; un grupo alquilo opcionalmente sustituido; R4 representa hidrogeno, o un sustituyente diferente de hidrogeno. R5 representa un grupo arilo opcionalmente sustituido, un grupo cicloalquilo opcionalmente sustituido, un grupo hetero-arilo opcionalmente sustituido, un grupo heterociclilo opcionalmente sustituido: un grupo alquilo opcionalmente sustituido; R6 representa hidrogeno, alquilo, cicloalquilo; R7 representa H, un grupo arilo opcionalmente sustituido, un grupo cicloalquilo opcionalmente sustituido, un grupo alquilo opcionalmente sustituido; y en el entendido de que si n representa O, R3a no representa hidroxilo; en forma de base libre o en forma de sal de adicion de ácido.
ARP080104490A 2007-10-16 2008-10-15 Derivados de 4-5-dihidro-5-oxo-imidazol,composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos como inhibidores de receptores de npy y2 no peptidicos, para el tratamiento de trastornos de ansiedad , depresion, trastornos metabolicos y endocrinos. AR068875A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07118616 2007-10-16

Publications (1)

Publication Number Publication Date
AR068875A1 true AR068875A1 (es) 2009-12-09

Family

ID=39144610

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104490A AR068875A1 (es) 2007-10-16 2008-10-15 Derivados de 4-5-dihidro-5-oxo-imidazol,composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos como inhibidores de receptores de npy y2 no peptidicos, para el tratamiento de trastornos de ansiedad , depresion, trastornos metabolicos y endocrinos.

Country Status (9)

Country Link
US (1) US7786155B2 (es)
EP (1) EP2212295A2 (es)
JP (1) JP2011500633A (es)
CN (1) CN101827826A (es)
AR (1) AR068875A1 (es)
CL (1) CL2008003055A1 (es)
PE (1) PE20090818A1 (es)
TW (1) TW200922560A (es)
WO (1) WO2009050201A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2212314A1 (en) * 2007-10-16 2010-08-04 Novartis AG Imidazolidine-2,4-dione (hydantoin) derivatives useful as npy y2 receptor modulators
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
NZ237476A (en) 1990-03-20 1994-01-26 Sanofi Sa N-substituted heterocyclic compounds and pharmaceutical compositions.
EP0640594A1 (en) 1993-08-23 1995-03-01 Fujirebio Inc. Hydantoin derivative as metalloprotease inhibitor
WO1997031910A1 (en) 1996-02-28 1997-09-04 Merck & Co., Inc. Fibrinogen receptor antagonists
DE19816929A1 (de) 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue substituierte Aminosäurederivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
AR035011A1 (es) 1999-06-30 2004-04-14 Daiichi Seiyaku Co Compuestos inhibidores de vla-4
WO2004058727A1 (en) 2002-12-20 2004-07-15 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
US7317025B2 (en) * 2003-09-24 2008-01-08 Johnson & Johnson Pharmaceutical Research & Development, Llc Non-peptidic NPY Y2 receptor inhibitors
US7592348B2 (en) * 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
WO2005090316A1 (en) * 2004-03-12 2005-09-29 Wyeth HYDANTOINS HAVING RNase MODULATORY ACTIVITY
WO2005114201A1 (en) 2004-05-21 2005-12-01 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor npy2 (npy2)
WO2006136553A1 (en) 2005-06-23 2006-12-28 Janssen Pharmaceutica N.V. Imidazolinone and hydantoine derivatives as novel inhibitors of histone deacetylase
TW200730523A (en) * 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
WO2007053436A1 (en) 2005-10-31 2007-05-10 Janssen Pharmaceutica N.V. Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP2212314A1 (en) * 2007-10-16 2010-08-04 Novartis AG Imidazolidine-2,4-dione (hydantoin) derivatives useful as npy y2 receptor modulators

Also Published As

Publication number Publication date
EP2212295A2 (en) 2010-08-04
JP2011500633A (ja) 2011-01-06
US7786155B2 (en) 2010-08-31
WO2009050201A2 (en) 2009-04-23
PE20090818A1 (es) 2009-07-24
CL2008003055A1 (es) 2009-06-05
WO2009050201A3 (en) 2009-08-13
TW200922560A (en) 2009-06-01
CN101827826A (zh) 2010-09-08
US20090099244A1 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
AR070479A1 (es) Derivado heterociclico fusionado y su uso
AR072224A1 (es) Derivados de pirimidona sustituidos
DK2134691T3 (da) Quinolinonderivativer som parp- og tank-inhibitorer
CO6260076A2 (es) Derivados de uracilo o timina para el tratamiento de la hepatitis c
UY31906A (es) Derivados de n-cicloalquil-3-fenilnicotinamida que inhiben pgds, sus composiciones, su uso para el tratamiento por ejemplo de afecciones alérgicas y respiratorias.
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
ECSP11011304A (es) Compuestos en calidad de antagonistas de bradiquinina b1
AR073136A1 (es) Compuestos de pirrol
AR064876A1 (es) Composiciones de amino alcohol y biocidas para sistemas de base acuosa
AR048669A1 (es) Derivados biciclicos de bisamida
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
CL2008002703A1 (es) Compuestos derivados de 1,4-dihidro-2h-piridazin-3-ona; composicion herbicida que comprende a dichos compuestos; metodo de control de malezas; uso de dichos compuestos para el control de malezas; y compuestos intermediarios.
CO6280399A2 (es) Peptidil nitrilos y uso de los mismos como inhibidores de peptidil peptidasa i
AR080596A1 (es) Compuestos alquilamido y composiciones farmaceuticas
ECSP077402A (es) Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica
CU23761B7 (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR073043A1 (es) Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras.
CO6300861A2 (es) Compuestos inhibidores de dipeptidil peptidasa iv metodos de preparacion de los mismos y composiciones farmaceuticas que los contienen como agentes activos
CR11636A (es) Compuestos triciclicos que tienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que contienen los mismos
CO6341610A2 (es) Compuesto heterociclilo aromatico que contiene nitrogeno.
AR084152A1 (es) Compuestos de triazolopirimidina como inhibidores de pde10a, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades del snc
AR076263A1 (es) Composiciones y metodos para tratar cancer. uso.
MX2013007296A (es) Derivado novedoso de isoquinolina sustituido.
AR072880A1 (es) Derivados nitrogenados de la pancratistatina
AR077429A1 (es) Compuestos hidroxiasenapina sus derivados y composiciones farmaceuticas que comprenden los mismos

Legal Events

Date Code Title Description
FB Suspension of granting procedure